Key Takeaways GKOS posted 25% YoY revenue growth in Q1 2025 to $106.7M, led by $21M in iDose TR sales. GKOS is advancing a rich pipeline, including Epioxa and PRESERFLO, to fuel long-term growth. GKOS expects mid-single-digit 2025 declines in non-iDose revenues due to LCD and legacy MIGS pressure.Glaukos Corporation (GKOS) continues to reshape the ophthalmology landscape, backed by a record-breaking first-quarter 2025 performance. The company posted revenues of $106.7 million, reflecting a 25% year-over-y ...

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 34.9% so far this year compared with the industry’s 7.5% decline. The S&P 500 Index has increased 0.7% in the same time frame.Glaukos, with a market capitalization of $5.48 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-q ...

Glaukos Corporation (GKOS) reported first-quarter 2025 adjusted loss of 22 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 33 cents. The figure also improved from the year-ago quarter’s adjusted loss of 70 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The GAAP loss per share was 32 cents compared with the prior-year quarter’s reported loss of 82 cents.Revenue DetailsGlaukos registered revenues of $106.7 million in the first quart ...

Glaukos (GKOS) Conference December 14, 2023 08:30 AM ET Speaker0 Good morning, and welcome to the Glaukos Corporation's Conference Call to discuss FDA approval of iDose TR. Copies of the company's press release are available at www.glaukos.com. This call is being recorded and an archived replay will be available online in the Investor Relations section at www.glaukos.com. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer sess ...